Trial Profile

A prospective, open label study for evaluation of the Acute Inhibitory and Chronic in-Ductive Effects of Rifampin on Letermovir

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letermovir (Primary) ; Rifampicin; Rifampicin
Indications Cytomegalovirus infections
Focus Pharmacokinetics

Most Recent Events

10 Dec 2021 Results published in the Clinical Pharmacology and Therapeutics
07 May 2020 New trial record
21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com